

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO		
10/674,433 10/01/2003		Arpi Matossian-Rogers	2003_1279	5502		
513	7590 11/17/2005		EXAM	EXAMINER		
WENDERO 2033 K STRE	TH, LIND & PONAC	HADDAD, MAHER M				
SUITE 800	315 1 N. W.		ART UNIT	PAPER NUMBER		
WASHINGTON, DC 20006-1021			1644			

DATE MAILED: 11/17/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	on No.	Applicant(s)					
Office Action Summary		10/674,43	10/674,433 MATOSSIAN-F		GERS, ARPI				
		Examiner		Art Unit					
		Maher M.		1644					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply									
A SHO WHIC - Exter after - If NO - Failui Any r	ORTENED STATUTORY PERIOD FOR RICHEVER IS LONGER, FROM THE MAILIN isions of time may be available under the provisions of 37 CF (SIX (6) MONTHS from the mailing date of this communication period for reply is specified above, the maximum statutory preserved by the office later than three months after the end patent term adjustment. See 37 CFR 1.704(b).	G DATE OF THE FR 1.136(a). In no even on. leriod will apply and wistatute, cause the app	IIS COMMUNICATION ont, however, may a reply be timed to the surprise SIX (6) MONTHS from the ication to become ABANDONE	N. nely filed the mailing date of this c D (35 U.S.C. § 133).					
Status									
2a)	Responsive to communication(s) filed on this action is FINAL . 2b) Since this application is in condition for all closed in accordance with the practice under the condition of the closed in accordance with the practice.	This action is nowance except	on-final. for formal matters, pro		e merits is				
Dispositi	on of Claims								
5) 6) 7)	Claim(s) <u>1-10,12,14,15 and 17-29</u> is/are p 4a) Of the above claim(s) is/are with Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) <u>1-10, 12, 14-15, 17-29</u> are subject	hdrawn from co	nsideration.	ment.	,				
Applicati	on Papers		·						
9)□	The specification is objected to by the Exa	miner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
11)	Replacement drawing sheet(s) including the co								
Priority u	ınder 35 U.S.C. § 119								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 									
2) Notic 3) Inform	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-94t nation Disclosure Statement(s) (PTO-1449 or PTO/S r No(s)/Mail Date		4) Interview Summary Paper No(s)/Mail Do 5) Notice of Informal P 6) Other:	ate	O-152)				

Page 2

Application/Control Number: 10/674,433

Art Unit: 1644

DETAILED ACTION

- 1. Claims 1-10, 12, 14-15 and 17-29 are pending.
- 2. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
 - I. Claims 1-10, drawn to a monoclonal or polyclonal antibody with reactivity against an anti-TCR Vβ antibody for use as a pharmaceutical or as a diagnostic agent, classified in Class 530, subclass 387.2.
 - II. Claims 1-10, drawn to <u>a ligand</u> with reactivity against an anti-TCR Vβ antibody for use as a pharmaceutical or as a diagnostic agent, classified in Class 530, subclasses 324-330 and 350.
 - III. Claim 12, drawn to a peptide, oligopeptide, polypeptide or protein that bound by a monoclonal or polyclonal antibody with reactivity against an anti-TCR Vβ antibody, which is not an anti-TCT Vβ antibody; classified in Class 530, subclasses 324-330 and 350.
 - IV. Claims 14 and 15, drawn to a peptide, oligopeptide, polypeptide or protein comprising the sequence of ESRP1; classified in Class 530, subclasses 324-330 and 350.
 - V. Claim 17, drawn to a cDNA, RNA or genomic DNA sequence encoding a monoclonal or polyclonal <u>antibody</u> with reactivity against <u>an anti-TCR Vβ antibody</u>; classified in Class 536, subclass 23.5.
 - VI. Claim 17, drawn to a cDNA, RNA or genomic DNA sequence encoding <u>a ligand</u> with reactivity against <u>an anti-TCR Vβ antibody</u>; classified in Class 536, subclass 23.5.
 - VII. Claim 17, drawn to a cDNA, RNA or genomic DNA sequence encoding a peptide, oligopeptide, polypeptide or protein that is bound by a mounoclonal or polyclonal antibody or equivalent ligand with reactivity against an anti-TCR Vβ antibody, which is not an anti-TCR Vβ antibody; classified in Class 536, subclass 23.5.
 - VIII. Claims 18-22, drawn to a cDNA, RNA, or genomic DNA sequence encoding ESRP1, vectors, bacteriophage clones, host cells, classified in Class 536, subclass 23.5; Class 435, subclasses 69.1, 455, 252.3, and 320.1.
 - IX. Claims 23-28, drawn to a method for detection of a naturally-occurring autoantibody comprising contacting a sample with a monoclonal or polyclonal <u>antibody</u> with reactivity against an anti-TCR V β antibody, classified in Class 435, subclass 7.1.

Application/Control Number: 10/674,433 Page 3

Art Unit: 1644

X. Claims 23-28, drawn to a method for detection of a naturally-occurring autoantibody comprising contacting a sample with <u>a ligand</u> with reactivity against an anti-TCR Vβ antibody, classified in Class 435, subclass 7.1.

- XI. Claims 29, drawn to method of treatment of an <u>autoimmune disease</u> comprising administering to a patient an effective amount of *the antibody* with reactivity against an anti-TCR Vβ antibody, classified in Class 424, subclass 131.1.
- XII. Claims 29, drawn to method of treatment of a <u>cardiovascular disease</u> comprising administering to a patient an effective amount of *the antibody* with reactivity against an anti-TCR Vβ antibody, classified in Class 424, subclass 131.1.
- XIII. Claims 29, drawn to method of treatment of <u>cancer</u> comprising administering to a patient an effective amount of *the antibody* with reactivity against an anti-TCR Vβ antibody, classified in Class 424, subclass 131.1.
- XIV. Claims 29, drawn to method of treatment of <u>other suitable disease</u> comprising administering to a patient an effective amount of *the antibody* with reactivity against an anti-TCR Vβ antibody, classified in Class 424, subclass 131.1.
- XV. Claim 29, drawn to method of treatment of an <u>autoimmune disease</u> comprising administering to a patient an effective amount of an equivalent ligand with reactivity against an anti-TCR Vβ antibody, classified in Class 424, subclass 185.1.
- XVI. Claim 29, drawn to method of treatment of a <u>cardiovascular disease</u> comprising administering to a patient an effective amount of an equivalent ligand with reactivity against an anti-TCR Vβ antibody, classified in Class 424, subclass 185.1.
- XVII. Claim 29, drawn to method of treatment of <u>cancer</u> comprising administering to a patient an effective amount of an equivalent ligand with reactivity against an anti-TCR Vβ antibody, classified in Class 424, subclass 185.1.
- XVIII. Claim 29, drawn to method of treatment of <u>other suitable disease</u> comprising administering to a patient an effective amount of an equivalent ligand with reactivity against an anti-TCR Vβ antibody, classified in Class 424, subclass 185.1.
- 3. Groups I-VIII are different products. Nucleic acids, polypeptides, and antibodies differ with respect to their structures and physicochemical properties; therefore each product is patentably distinct.
- 4. Groups IX-XVIII are different methods. Various methods of detecting and various methods of treating differ with respect to ingredients, method steps, and endpoints; therefore, each method is patentably distinct.

Application/Control Number: 10/674,433

Art Unit: 1644

- 5. Groups I/(IX and XI-XIV) and II/(X and XV-XVIII) are related as product and process of using. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the antibody of Group I and the ligand of Group II can be used for affinity purification, in addition to the various methods of treating and detecting recited.
- 6. These inventions are distinct for the reasons given above. In addition, they have acquired a separate status in the art as shown by different classification and/or recognized divergent subject matter. Further, even though in some cases the classification is shared, a different field of search would be required based upon the structurally distinct products recited and the various methods of use comprising distinct method steps. Therefore restriction for examination purposes as indicated is proper. Further, a prior art search also requires a literature search. It is an undue burden for the examiner to search more than one invention.

Species Election

- 7. Irrespective of whichever group applicant may elect, applicant is further required under 35 US 121 (1) to elect a single disclosed species to which claims would be restricted if no generic claim is finally held to be allowable and (2) to list all claims readable thereon including those subsequently added.
 - A. If any one of Groups XI or XV is elected, applicant is required to elect a single specific autoimmune disease such a) IDDM, b) NIDDM, c) organ specific or d) non-organ specific autoimmune disease. These species are distinct because the pathological conditions differ in etiologies and therapeutic endpoints; thus each condition represents patentably distinct subject matter.

Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

8. Applicant is advised that a response to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 C.F.R. § 1.141. If claims are added after the

Application/Control Number: 10/674,433

Art Unit: 1644

election, applicant must indicate which are readable upon the elected species. M.P.E.P. § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. § 103 of the other invention.

- 9. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 10. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01. 12. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Page 6

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maher Haddad whose telephone number is (571) 272-0845. The examiner can normally be reached Monday through Friday from 7:30 am to 4:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

November 11, 2005

Maher Haddad

Maher Haddad, Ph.D. Patent Examiner Technology Center 1600